Skip to content
Inciteful Med

Modern Care: Modulators, Maintenance, and the New Nutrition

Last updated:

Modern cystic fibrosis care relies on a combination of CFTR modulators to target the underlying genetic defect, daily airway clearance techniques to keep lungs clear, and pancreatic enzymes for digestion. Nutritional goals have also shifted toward a balanced diet to support long-term health.

Key Takeaways

  • • CFTR modulators target the underlying protein defect in cystic fibrosis but require consistent use and are not a cure.
  • • Patients on modulators need regular monitoring for liver function and potential neuropsychiatric side effects like brain fog or anxiety.
  • • Daily airway clearance techniques and inhaled medications remain essential for preventing mucus buildup, even when taking modulators.
  • • Most people with CF require pancreatic enzyme replacement therapy with every meal to properly absorb nutrients.
  • • Because modulators can cause rapid weight gain, modern CF nutrition focuses on a balanced diet rather than the traditional high-calorie approach.

Managing cystic fibrosis (CF) today is a balancing act between high-tech “modulator” drugs and the essential daily routines that keep the body functioning. While new treatments have revolutionized the outlook for many, the “standard of care” remains a comprehensive, lifelong commitment [1][2].

CFTR Modulators: The Modern Game-Changers

The most significant shift in CF care is the use of CFTR modulators, such as the triple-combination therapy elexacaftor/tezacaftor/ivacaftor (ETI), commonly known as Trikafta [3][4].

  • How They Work: Unlike older treatments that only addressed symptoms, modulators target the underlying protein defect, helping the “salt channels” in your cells work more effectively [1][5].
  • Eligibility: These drugs are precisely tailored to your genetics. For example, ETI is currently indicated for those with at least one copy of the F508del mutation [4][6].
  • Access and Cost: While these medications are a major scientific breakthrough, they are also very expensive [7]. However, you do not have to navigate this alone. Your CF care team includes dedicated social workers and pharmacists who will help you access patient assistance programs and navigate complex insurance approvals [8].
  • Important Note: While modulators are transformative, they are not a cure [1][9]. They must be taken consistently to maintain their benefits, and approximately 10–18% of the CF community has mutations that do not yet respond to current modulators [10][11].

Monitoring Side Effects

While modulators are generally well-tolerated, they require medical supervision [12][13]. Common side effects include:

  • Physical Symptoms: Headaches, skin rashes, upper respiratory infections, and stomach pain [12][13].
  • Liver Health: Modulators can cause elevated transaminases (liver enzymes), so your doctor will perform regular blood tests to monitor your liver function [14][15].
  • Mental Health: Some patients report neuropsychiatric effects such as “brain fog,” anxiety, or depression [16][12].

The Core Daily Routine: ACTs and Enzymes

Even with the success of modulators, “traditional” therapies are still the backbone of health for most patients [1][17].

  1. Airway Clearance Techniques (ACTs): These are physical methods—like using a vibrating vest or specific breathing exercises—to loosen and move mucus out of the lungs [18][19]. Skipping ACTs can allow mucus to build up, even if you feel healthy [18].
  2. Inhaled Medications: Many patients use a specific, strict sequence of inhaled treatments to open and clear the lungs safely [18][19]:
    • Step 1: Bronchodilator (like albuterol) to open the airways and prevent severe bronchospasm.
    • Step 2: Mucus thinner (like hypertonic saline or dornase alfa) to break up clogs.
    • Step 3: ACTs (the physical clearance).
    • Step 4: Inhaled antibiotics (if prescribed) to treat any lingering bacteria in the newly cleared lungs.
  3. Pancreatic Enzyme Replacement Therapy (PERT): Because CF often blocks the release of digestive enzymes, most people must take PERT (pills like Creon or Zenpep) with every meal and snack to absorb nutrients [20][21]. If you experience symptoms of pancreatic insufficiency—such as severe gas, stomach pain, greasy or floating stools, or an inability to gain weight despite eating well—you should advocate for a stool test to see if you need enzymes [22][17].

The Great Nutrition Shift

For decades, CF nutrition focused on a “high-calorie, high-fat” diet to combat malnutrition [23]. However, modulators have changed the rules:

  • Weight Gain: Modulators often lead to a rapid increase in BMI (Body Mass Index) and fat mass [23][24].
  • New Risks: Clinicians are now seeing an increase in “overnutrition” issues, such as high blood pressure and elevated cholesterol [23][4].
  • The Goal: Modern nutrition guidance is shifting toward a balanced diet focused on long-term heart and metabolic health, rather than just “getting enough calories” [4][25].
Therapy Type Common Options Purpose
Genetic CFTR Modulators (e.g., Trikafta) Fixes the faulty protein [3]
Airway Vest, PEP valve, Active Cycle of Breathing Clears mucus physically [18]
Inhaled Bronchodilators, Hypertonic saline, Pulmozyme Opens airways and thins mucus for easier clearing [19]
Digestive Pancreatic enzymes (PERT) Helps absorb fat and nutrients [20]
Nutritional Balanced diet, fat-soluble vitamins Maintains energy and growth [4]

Frequently Asked Questions

Am I eligible for CFTR modulator therapy like Trikafta?
Eligibility for CFTR modulators depends on your specific genetics. For example, the triple-combination therapy Trikafta is indicated for patients with at least one copy of the F508del mutation. Your CF care team will use your genetic test results to determine if these medications are right for you.
What are the side effects of CFTR modulators?
While generally well-tolerated, modulators can cause physical symptoms like headaches, stomach pain, and elevated liver enzymes. Some patients also report neuropsychiatric effects such as brain fog, anxiety, or depression, making medical monitoring essential.
Do I still need to do airway clearance if I take a CFTR modulator?
Yes, airway clearance techniques remain a crucial part of your daily routine. Skipping these physical methods can allow mucus to build up in your lungs, even if you feel healthy and are taking a modulator.
How has the recommended diet for cystic fibrosis changed?
Historically, patients were encouraged to eat a high-calorie, high-fat diet to prevent malnutrition. Because modern modulators often lead to rapid weight gain and increased BMI, the new nutritional goal is a balanced diet focused on long-term heart and metabolic health.
How do I know if I need pancreatic enzymes?
Signs that you may need pancreatic enzyme replacement therapy include severe gas, stomach pain, greasy or floating stools, or difficulty gaining weight despite eating well. If you experience these symptoms, ask your doctor for a stool test to check for pancreatic insufficiency.

Questions for Your Doctor

  • • Am I (or is my child) eligible for triple-combination modulator therapy based on our genetic mutations?
  • • How often should we monitor liver enzymes and blood pressure while on modulators?
  • • Can we safely reduce or stop any inhaled treatments or airway clearance if lung function is stable?
  • • What should our new nutritional goals be now that weight gain is more likely?
  • • Are there specific signs of neuropsychiatric side effects, like anxiety or 'brain fog,' that we should watch for?
  • • Who is the social worker on my team that can help with insurance approvals for my medications?

Questions for You

  • • How has my daily energy level or cough changed since starting new treatments?
  • • Am I finding it harder or easier to maintain a healthy weight than I used to?
  • • What parts of my daily treatment routine feel the most burdensome, and can I discuss 'treatment fatigue' with my team?
  • • How consistent am I with my airway clearance, even on days when I feel 'fine'?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis.

    Armbruster CR, Hilliam YK, Zemke AC, et al.

    mBio 2024; (15(5)):e0051924 doi:10.1128/mbio.00519-24.

    PMID: 38564694
  2. 2

    [Evidence-based treatment of cystic fibrosis].

    Ringshausen FC, Hellmuth T, Dittrich AM

    Der Internist 2020; (61(12)):1212-1229 doi:10.1007/s00108-020-00896-9.

    PMID: 33201261
  3. 3

    Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.

    Wang X, Tse C, Singh A

    Journal of medicinal chemistry 2025; (68(3)):2255-2300 doi:10.1021/acs.jmedchem.4c02547.

    PMID: 39882833
  4. 4

    Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.

    Grancini V, Gramegna A, Zazzeron L, et al.

    Diabetes & metabolism 2023; (49(5)):101466 doi:10.1016/j.diabet.2023.101466.

    PMID: 37536552
  5. 5

    Advances in the Cystic Fibrosis Drug Development Pipeline.

    Esposito C, Kamper M, Trentacoste J, et al.

    Life (Basel, Switzerland) 2023; (13(9)) doi:10.3390/life13091835.

    PMID: 37763239
  6. 6

    Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.

    Stekolchik E, Saul D, Chidekel A

    Respiratory medicine case reports 2022; (40()):101775 doi:10.1016/j.rmcr.2022.101775.

    PMID: 36411821
  7. 7

    Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.

    Smith S, Borchardt M

    Journal of managed care & specialty pharmacy 2022; (28(7)):721-731 doi:10.18553/jmcp.2022.28.7.721.

    PMID: 35737861
  8. 8

    Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.

    Çobanoğlu N, Özçelik U, Çakır E, et al.

    Pediatric pulmonology 2020; (55(9)):2302-2306 doi:10.1002/ppul.24854.

    PMID: 32453906
  9. 9

    Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.

    Hisert KB, Birket SE, Clancy JP, et al.

    The Lancet. Respiratory medicine 2023; (11(10)):916-931 doi:10.1016/S2213-2600(23)00324-7.

    PMID: 37699420
  10. 10

    Non-Modulator Therapies: Developing a Therapy for Every Cystic Fibrosis Patient.

    Egan ME

    Clinics in chest medicine 2022; (43(4)):717-725 doi:10.1016/j.ccm.2022.06.011.

    PMID: 36344076
  11. 11

    Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor.

    Sanders DB, Mayer-Hamblett N, Rosenfeld M, et al.

    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2025; (24(2)):255-262 doi:10.1016/j.jcf.2024.07.015.

    PMID: 39079877
  12. 12

    New Tic Disorder in a Child With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor.

    Duehlmeyer SR, Elson EC, Oermann CM

    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2024; (29(1)):82-84 doi:10.5863/1551-6776-29.1.82.

    PMID: 38332957
  13. 13

    Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy.

    Ridley K, Condren M

    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2020; (25(3)):192-197 doi:10.5863/1551-6776-25.3.192.

    PMID: 32265602
  14. 14

    A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.

    Gavioli EM, Guardado N, Haniff F, et al.

    Journal of clinical pharmacy and therapeutics 2021; (46(2)):286-294 doi:10.1111/jcpt.13329.

    PMID: 33285018
  15. 15

    Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis.

    Coughlin MP, Sankararaman S, Roesch EA, et al.

    Frontiers in pediatrics 2024; (12()):1457517 doi:10.3389/fped.2024.1457517.

    PMID: 39507496
  16. 16

    Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice.

    Ge Q, Fagan A, Lu H, et al.

    Acta psychologica 2026; (263()):106210 doi:10.1016/j.actpsy.2026.106210.

    PMID: 41534408
  17. 17

    Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine.

    Ritivoiu ME, Drăgoi CM, Matei D, et al.

    Pharmaceutics 2023; (15(1)) doi:10.3390/pharmaceutics15010162.

    PMID: 36678791
  18. 18

    Inhaled medications in cystic fibrosis beyond antibiotics.

    Sepe A, Villella VR, Cimbalo C, et al.

    Minerva pediatrica 2019; (71(4)):371-375 doi:10.23736/S0026-4946.19.05509-9.

    PMID: 30761821
  19. 19

    Immediate effect of inhalation therapy combined with oscillatory positive expiratory pressure on the respiratory system of children with cystic fibrosis.

    Gonçalves Wamosy RM, Castilho T, Almeida ACDS, et al.

    International journal of clinical practice 2021; (75(10)):e14659 doi:10.1111/ijcp.14659.

    PMID: 34322960
  20. 20

    Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis.

    Cecchetti M, Scarallo L, Lionetti P, et al.

    Paediatric respiratory reviews 2025; (54()):70-75 doi:10.1016/j.prrv.2024.07.004.

    PMID: 39341749
  21. 21

    Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth.

    Biquand E, Khau S, Fouquenet D, et al.

    Microbiology spectrum 2025; (13(9)):e0227524 doi:10.1128/spectrum.02275-24.

    PMID: 40736245
  22. 22

    Acute Appendicitis Masquerading Distal Intestinal Obstruction Syndrome in Adult Cystic Fibrosis.

    Nanavati SM, Patel H, Melki G, et al.

    Case reports in gastrointestinal medicine 2018; (2018()):8475060 doi:10.1155/2018/8475060.

    PMID: 30356411
  23. 23

    Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.

    Petersen MC, Begnel L, Wallendorf M, Litvin M

    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2022; (21(2)):265-271 doi:10.1016/j.jcf.2021.11.012.

    PMID: 34862121
  24. 24

    Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.

    Olivier M, Kavvalou A, Welsner M, et al.

    Frontiers in pharmacology 2023; (14()):1176815 doi:10.3389/fphar.2023.1176815.

    PMID: 37229253
  25. 25

    Year in review 2023 - Back to the future.

    Cristiani L, Fernandes FF

    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2024; (23(2)):203-207 doi:10.1016/j.jcf.2024.02.007.

    PMID: 38431442

This page provides educational information about cystic fibrosis treatments and daily care routines. Always consult your pulmonologist or CF care team before changing your medications, diet, or clearance routine.

Stay up to date

Get notified when new research about Cystic fibrosis is published.

No spam. Unsubscribe anytime.